Piramal Biotech Of India Sees First Drug To Market By 2011
This article was originally published in PharmAsia News
Executive Summary
India's Piramal Life Sciences expects to get its first drug to market by 2011, the company says. The firm, the free-standing biotech created when Piramal Healthcare separated the research portion of its business last year, has its P276 molecule in Phase II trials for treating several cancers, including head and neck cancer for which there is no treatment without a lot of side effects. Managing Director Somesh Sharma said the company hoped to take advantage of those segments of the drug market. He said the company expects to become financially viable by 2011 at the latest. (Click here for more